In the PrEP Impact Trial, Oral PrEP Was Highly Effective Among At-Risk MSM

PrEP was highly effective in an implementation study focusing on MSM in England, but a substantial unmet need for wider use was defined.

Appropriate use of oral PrEP with TDF/FTC prevents HIV infection, but obstacles to wide use include low acceptance rates and resource limitations. In the PrEP Impact Trial (a prospective implementation study), investigators utilized the specialist health services (SHS) network throughout England to enroll persons designated at risk for HIV infection from October 2017 to July 2020; participants received daily or event-driven TDF/FTC. This analysis involved 21,356 persons enrolled before February 29, 2020. Most (95.5%) were men who have sex with men (MSM).

PrEP uptake was 57% among eligible persons whose coverage extended for the majority of follow-up. For MSM, HIV incidence was 0.13/100 person-years (of the 27 seroconversions, most occurred i…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

In the PrEP Impact Trial, Oral PrEP Was Highly Effective Among At-Risk MSM

Topics

Reviewing Author